Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to six new employees. The Compensation Committee approved stock options for 16,960 shares at an exercise price of $7.04 per share, reflecting the closing price on April 8, 2025. Additionally, the employees received restricted stock units totaling 8,530 shares. These equity awards were issued under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS), un'azienda biofarmaceutica in fase clinica focalizzata sulle terapie oncologiche, ha concesso premi azionari a sei nuovi dipendenti. Il Comitato per la Compensazione ha approvato opzioni su azioni per 16.960 azioni a un prezzo di esercizio di $7.04 per azione, che riflette il prezzo di chiusura dell'8 aprile 2025. Inoltre, i dipendenti hanno ricevuto unità azionarie vincolate per un totale di 8.530 azioni. Questi premi azionari sono stati emessi nell'ambito del Piano di Induzione 2020 dell'azienda, istituito a gennaio 2020 secondo l'eccezione di induzione della Regola 303A.08 del Manuale delle Aziende Quotabili della NYSE.
Arcus Biosciences (NYSE:RCUS), una empresa biofarmacéutica en etapa clínica centrada en terapias contra el cáncer, ha otorgado premios en acciones a seis nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones para 16,960 acciones a un precio de ejercicio de $7.04 por acción, lo que refleja el precio de cierre del 8 de abril de 2025. Además, los empleados recibieron unidades de acciones restringidas que totalizan 8,530 acciones. Estos premios en acciones se emitieron bajo el Plan de Inducción 2020 de la empresa, que se estableció en enero de 2020 bajo la excepción de inducción de la Regla 303A.08 del Manual de Empresas Listadas de la NYSE.
Arcus Biosciences (NYSE:RCUS), 암 치료에 집중하는 임상 단계의 바이오 제약 회사,는 여섯 명의 신입 직원에게 주식 보상을 부여했습니다. 보상 위원회는 2025년 4월 8일의 종가를 반영하여 주당 $7.04의 행사가로 16,960주에 대한 주식 옵션을 승인했습니다. 또한, 직원들은 총 8,530주의 제한된 주식 단위를 받았습니다. 이러한 주식 보상은 NYSE 상장 회사 매뉴얼 규칙 303A.08의 유인 예외에 따라 2020년 1월에 설립된 회사의 2020 유인 계획에 따라 발행되었습니다.
Arcus Biosciences (NYSE:RCUS), une entreprise biopharmaceutique en phase clinique axée sur les thérapies contre le cancer, a accordé des récompenses en actions à six nouveaux employés. Le Comité de Rémunération a approuvé des options d'achat d'actions pour 16 960 actions à un prix d'exercice de $7.04 par action, reflétant le prix de clôture du 8 avril 2025. De plus, les employés ont reçu des unités d'actions restreintes totalisant 8 530 actions. Ces récompenses en actions ont été émises dans le cadre du Plan d'Induction 2020 de l'entreprise, qui a été établi en janvier 2020 conformément à l'exception d'incitation de la Règle 303A.08 du Manuel des Sociétés Cotées de la NYSE.
Arcus Biosciences (NYSE:RCUS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Krebstherapien konzentriert, hat sechs neuen Mitarbeitern Aktienvergütungen gewährt. Der Vergütungsausschuss genehmigte Aktienoptionen für 16.960 Aktien zu einem Ausübungspreis von $7.04 pro Aktie, was dem Schlusskurs vom 8. April 2025 entspricht. Darüber hinaus erhielten die Mitarbeiter eingeschränkte Aktieneinheiten in Höhe von insgesamt 8.530 Aktien. Diese Aktienvergütungen wurden im Rahmen des Induktionsplans 2020 des Unternehmens ausgegeben, der im Januar 2020 gemäß der Induktionsausnahme der Regel 303A.08 des Handbuchs für börsennotierte Unternehmen der NYSE eingerichtet wurde.
- None.
- None.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409706269/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Maryam Bassiri
AD, Corporate Communications
(510) 406-8520
mbassiri@arcusbio.com
Source: Arcus Biosciences
FAQ
What equity awards did Arcus Biosciences (RCUS) grant to new employees in April 2025?
What was the exercise price for RCUS stock options granted on April 8, 2025?
Under which plan were the RCUS equity awards granted in April 2025?
How many restricted stock units (RSUs) did Arcus Biosciences award in April 2025?
